BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
'It's doing badly': Fears grow for whale stuck off Germany's coast - 2Consumer outlook on UK economy falls to two-year low
- 3At least 55 injured in Russia after train crashes, overturns
- 4Is Iran using cryptocurrencies to circumvent sanctions?
- 5'Home Alone' actor Joe Pesci said 'no' to this stunt until he saw a 9-year-old girl do it, says director Chris Columbus
- From White Elephant to Favorite Things parties, here are all the rules you need to know every kind of gift exchange
- IAF intercepts over 90% of drones launched by Iran, Hezbollah during Operation Roaring Lion
- 4 injured in shooting at North Carolina tree lighting ceremony
- 3 moms, 3 countries, 1 very familiar problem: Why child care costs still don't add up for families
- Interstellar comet 3I/ATLAS isn't an alien spacecraft, astronomers confirm. 'In the end, there were no surprises.'
- New peace laureate: Iran's arrest of Mohammadi 'confession of fear'
- Dutch police probe a small blast outside a pro-Israel Christian center
- Smooth out Your Funds: Cash The board Simplified
- Fascinating Fishing Objections From Around The World
